Psychostimulants for Depression in Hospitalized Cancer Patients

Olin, Jonathan; Masand, Prakash S.

doi:10.1016/s0033-3182(96)71599-2

Cited by 109 publications

(53 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There is also evidence to suggest that methylphenidate improves depression in many patient groups including: stroke patients (Lazarus et al, 1992;Masand and Chaudhary, 1994), cancer patients (Fernandez and Adams, 1986;Fernandez et al, 1987;Olin and Masand, 1996), those with HIV infection (Holmes et al, 1989;Fernandez et al, 1995) and secondary to surgery or medical illness (Kaufmann et al, 1984;Woods et al, 1986;Masand et al, 1991). Finally, it may be effective in the treatment of neurocardiogenic syncope (Grubb et al, 1996) and for reducing the duration of coma (Worzniak et al, 1997).…”

Section: Further Applications Of Methylphenidatementioning

confidence: 99%

See 1 more Smart Citation

Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects

Leonard¹,

McCartan²,

White³

et al. 2004

Human Psychopharmacology

210

145

View full text Add to dashboard Cite

Section: Further Applications Of Methylphenidatementioning

confidence: 99%

“…Methylphenidate is useful in the treatment of depression in cancer patients (Fernandez et al, 1987;Stiebel and Kemp, 1990;Olin and Masand, 1996;Macleod, 1998). Furthermore, Fernandez and Adams (1986) report improvements in both depression and cognitive impairment following methylphenidate administration.…”

Section: Further Applications Of Methylphenidatementioning

confidence: 99%

Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects

Leonard¹,

McCartan²,

White³

et al. 2004

Human Psychopharmacology

210

145

View full text Add to dashboard Cite

“…Further, psychostimulants may in fact improve appetite in some patients. In a retrospective chart review, 54 % of cancer in patients treated with dextroamphetamine or methylphenidate had improvement in appetite [67].…”

Section: Pharmacologic Treatment Of Cancer-related Fatiguementioning

confidence: 99%

Sick and Tired: Mood, Fatigue, and Inflammation in Cancer

Kruse

Strouse

2015

Curr Psychiatry Rep

View full text Add to dashboard Cite

Cancer patients commonly experience depression and fatigue before, during, and after treatment. Symptoms can be debilitating, and the risks associated with unrecognized or inadequately treated depression are substantial. Inflammation may be important in the genesis of depression and fatigue in cancer patients; potential neurobiological mechanisms of inflammation-related behavioral symptoms are reviewed. Randomized studies of pharmacologic treatments for depression in cancer populations are limited, but available data are generally encouraging. Studies of pharmacologic treatments for cancer-related fatigue have been more numerous but with mixed results. A practical approach to pharmacologic treatment of depression and fatigue in cancer patients involves weighing the potential risks and benefits of specific agents, including potential for adverse or advantageous side effects. Progress in understanding the neurobiological mechanisms underlying inflammation-related behavioral symptoms will provide opportunities for the development of novel and targeted treatments.

show abstract

“…The use of dexedrine (Kaufmann et al, 1984;Little, 1993;Olin and Masand, 1996;Woods et al, 1986) and methylphenidate (Askinazi et al, 1986;El-Mallakh, 2000;Kaufmann et al, 1984;Lazarus et al, 1992Lazarus et al, , 1994Lingam et al, 1988;Little, 1993;Masand et al, 1991a,b;Pickett et al, 1990;Rothenhausler et al, 2000;Stoll et al, 1996;Woods et al, 1986) in depression, particularly in depressed patients with comorbid medical illness, is supported by large chart reviews and small open trials cumulatively containing hundreds of patients. There is also anecdotal evidence to support the use of adjunct stimulants to the TCAs (Feighner et al, 1985), SSRIs (Lavretsky and Kumar, 2001;Lavretsky et al, 2003;Masand et al, 1998) and MAOIs (Fawcett et al, 1991;Feighner et al, 1985) for the treatment of MDD.…”

Section: Dopaminergic Agentsmentioning

confidence: 99%

Monoaminergic‐based Pharmacotherapy for Depression

Papakostas¹,

Fava²

2005

Biology of Depression

View full text Add to dashboard Cite

Although recent advances in neuropharmacology, neuroendocrinology, molecular biology, and pharmacogenetics have been instrumental in bringing about potential treatments for depression which are fundamentally unrelated to their predecessors, including substance P antagonists, glutaminergic agents, and corticotropinreleasing factor (CRF) antagonists, nevertheless it was agents that influenced the function of monoamine receptors and transporters that were discovered initially by serendipity and then developed as treatments for depression. The development of such compounds also served as a framework for the understanding of depression as a medical illness affecting brain functioning. As a result of these efforts, our field has gained further understanding of the role of monoamines in depression. In previous chapters, the relevance of monoamines in the underlying pathophysiology of depression was reviewed. In the following chapter we will focus on describing the contemporary role of monoaminergic agents in the treatment of depression. 6.

show abstract

Psychostimulants for Depression in Hospitalized Cancer Patients

Cited by 109 publications

References 8 publications

Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects

Methylphenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects

Sick and Tired: Mood, Fatigue, and Inflammation in Cancer

Monoaminergic‐based Pharmacotherapy for Depression

Contact Info

Product

Resources

About